Nectar Raises Over $16.5M in Series A Funding
- Nectar, a New York-based provider of an allergy care platform, raised $16.5m in Series A funding
- The round, which brought total equity raised to over $24m, was led by Harmony Partners, with participation from Juxtapose and Obvious Ventures
- The company intends to use the funds to invest in three key areas in 2023, scaling its virtual care platform nationwide, launching its first physical location to comprehensively treat allergies, and initiating clinical studies
- The company is building a vertically-integrated platform for allergies, including a hybrid virtual and physical clinic model, compounding pharmacy
- The company offers custom-formulated drops for under the tongue, delivered right to patients’ homes
